An HPLC-UV method for the measurement of permeability of marker drugs in the Caco-2 cell assay

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 6, 2011, Pages 531-537

  Kratz, J M ^a   Teixeira, M R ^a   Koester, L S ^b   Simoes C M O ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Caco 2; HPLC UV; Marker drugs; Permeability

Indexed keywords

ACETONITRILE; ACICLOVIR; AMMONIUM ACETATE; CARBAMAZEPINE; GLYCOPROTEIN P; HYDROCHLOROTHIAZIDE; PROPRANOLOL; VERAPAMIL; VINBLASTINE;

ACCURACY; AQUEOUS SOLUTION; ARTICLE; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CHROMATOGRAPHY; CONTROLLED STUDY; ELUTION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PERMEABILITY BARRIER; PREDICTION; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 79958774075     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500060     Document Type: Article

References (32)

1. Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J 2006; 8: E1-13.
2. Press B, Di Grandi D. Permeability for intestinal absorption: Caco-2 assay and related issues. Curr Drug Metab 2008; 9: 893-900.
3. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96: 736-749.
4. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
5. Elsby R, Surry DD, Smith VN, Gray AJ. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 2008; 38: 1140-1164.
6. Matsson P, Bergstrom CA, Nagahara N, Tavelin S, Norinder U, Artursson P. Exploring the role of different drug transport routes in permeability screening. J Med Chem 2005; 48: 604-613.
7. FDA (Food and Drug Administration). Guidance for industry - Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000.
8. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
9. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236.
10. Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci 2008; 97: 712-725.
11. Corti G, Maestrelli F, Cirri M, Zerrouk N, Mura P. Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. Eur J Pharm Sci 2006; 27: 354-362.
12. Polli JE, Yu LX, Cook JA, Amidon GL, Borchardt RT, Burnside BA, et al. Summary workshop report: biopharmaceutics classification system - implementation challenges and extension opportunities. J Pharm Sci 2004; 93: 1375-1381.
13. FDA (Food and Drug Administration). Guidance for industry - Bioanalytical method validation. 2001.
14. ICH (International Conference on Harmonization). Validation of analytical procedures: text and methodology, Q2(R1). 2005.
15. Hubatsch I, Ragnarsson EG, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco- 2 monolayers. Nat Protoc 2007; 2: 2111-2119.
16. Grasjo J, Taipalensuu J, Ocklind G, Artursson P. Applications of epithelial cell culture in studies of drug transport. In: Wise C (Editor), Epithelial cell culture protocols. Totowa: Humana Press Inc.; 2002. p 233-272.
17. Bergstrom CA, Strafford M, Lazorova L, Avdeef A, Luthman K, Artursson P. Absorption classification of oral drugs based on molecular surface properties. J Med Chem 2003; 46: 558-570.
18. Ungell AL. Caco-2 replace or refine? Drug Discovery Today 2004; 1: 423-430.
19. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 1998; 41: 4939-4949.
20. Lee KJ, Johnson N, Castelo J, Sinko PJ, Grass G, Holme K, et al. Effect of experimental pH on the in vitro permeability in intact rabbit intestines and Caco-2 monolayer. Eur J Pharm Sci 2005; 25: 193-200.
21. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.
22. Skold C, Winiwarter S, Wernevik J, Bergstrom F, Engstrom L, Allen R, et al. Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. J Med Chem 2006; 49: 6660-6671.
23. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem 2008; 51: 5932-5942.
24. Moffat AC, Osselton MD, Widdop B (Editors). Clarke's analysis of drugs and poisons. Chicago: Pharmaceutical Press; 2003.
25. Bansal T, Singh M, Mishra G, Talegaonkar S, Khar RK, Jaggi M, et al. Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 859: 261-266.
26. Venkatesh G, Ramanathan S, Mansor SM, Nair NK, Sattar MA, Croft SL, et al. Development and validation of RPHPLC- UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies. J Pharm Biomed Anal 2007; 43: 1546-1551.
27. Chawla S, Ghosh S, Sihorkar V, Nellore R, Kumar TR, Srinivas NR. High-performance liquid chromatography method development and validation for simultaneous determination of five model compounds, antipyrine, metoprolol, ketoprofen, furosemide and phenol red, as a tool for the standardization of rat in situ intestinal permeability studies using timed wavelength detection. Biomed Chromatogr 2006; 20: 349-357.
28. Augustijns P, Mols R. HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. J Pharm Biomed Anal 2004; 34: 971-978.
29. Palmgren JJ, Monkkonen J, Jukkola E, Niva S, Auriola S. Characterization of Caco-2 cell monolayer drug transport properties by cassette dosing using UV/fluorescence HPLC. Eur J Pharm Biopharm 2004; 57: 319-328.
30. Thiel-Demby VE, Humphreys JE, St John Williams LA, Ellens HM, Shah N, Ayrton AD, et al. Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. Mol Pharm 2009; 6: 11-18.
31. Uchida M, Fukazawa T, Yamazaki Y, Hashimoto H, Miyamoto Y. A modified fast (4 day) 96-well plate Caco-2 permeability assay. J Pharmacol Toxicol Methods 2009; 59: 39-43.
32. Shirasaka Y, Sakane T, Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 2008; 97: 553-565.